TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17910225

Group type: EXPERIMENTAL
Intervention: Adhesive patch applied to Class II cavities
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (fillings without patch application)
Number of subjects: 20
Study: 12825024

Group type: EXPERIMENTAL
Intervention: International collaborative research working group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Collaborative projects
Number of subjects: 29
Study: 10376122

Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg p.o.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8917239

Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine/prilocaine (EMLA) cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1785238

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 44
Study: 6355269

Group type: EXPERIMENTAL
Intervention: C.B.S. tablets (1 four times daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: C.B.S. liquid (5 ml four times daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: C.B.S. tablets and liquid
Number of subjects: 51
Study: 30933856

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 28862100

Group type: EXPERIMENTAL
Intervention: Arthroscopy‐assisted intramedullary nailing (AIMN); n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional intramedullary nailing (IMN); n = 20
Number of subjects: 40
Study: 25218879

Group type: EXPERIMENTAL
Intervention: Non-taste sensory activity program (looking, listening, feeling, and smelling activities with unusual fruits and vegetables) for 4 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 92
Study: 23305152

Group type: EXPERIMENTAL
Intervention: Optimised person-centred intervention (WHELD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 16
Study: 22014267

Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gel containing unloaded fraction (SS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unloaded gallic acid (GS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel containing gallic acid loaded in non-elastic niosomes (GN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel containing gallic acid loaded in elastic niosomes (GE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN and SE)
Number of subjects: 0
Study: 19148479

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 236
Study: 16944236

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging by spectroscopy using filtered blue light (375‐440 nm)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging by spectroscopy
Number of subjects: 42
Study: 15614997

Group type: EXPERIMENTAL
Intervention: Supported-weight treadmill ambulation training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy subjects performing the same maneuver
Number of subjects: 9
Study: 11000320

Group type: EXPERIMENTAL
Intervention: Bioadhesive fluoride tablets (0.5 mg F) used for 5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no fluoride supplements) for 5 days
Number of subjects: 8
Study: 9181202

Group type: EXPERIMENTAL
Intervention: Clinician advice and nurse-assisted intervention
Number of subjects: 1978
Study: 1395766

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (up to 0.84 mg/kg in 10 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (300 mg of pulverized tablets)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous dipyridamole
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral dipyridamole
Number of subjects: 28
Study: 3901172

Group type: EXPERIMENTAL
Intervention: Sucralfate (300 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31393548

Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Number of subjects: 88

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 88
Study: 29665829

Group type: EXPERIMENTAL
Intervention: HeLP-her program (one group session, monthly SMS text messages, one phone coaching session, and a program manual)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: HeLP-her program (for women with BMI ≥ 25 kg/m2)
Number of subjects: 649

Group type: COMPARATOR
Intervention: General women's health education session (control)
Number of subjects: 649
Study: 26903172

Group type: EXPERIMENTAL
Intervention: Positive expectations regarding aging
Number of subjects: 0
Study: 25492049

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 39
Study: 22721642

Group type: EXPERIMENTAL
Intervention: LSM+miglitol (50 mg × 3)
Number of subjects: 111

Group type: COMPARATOR
Intervention: LSM
Number of subjects: 111
Study: 21992852

Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=168)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=164)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Fludarabine alone (n=165)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=158)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=157)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=163)
Number of subjects: 335
Study: 18504332

Group type: EXPERIMENTAL
Intervention: Survey on knowledge about ACS symptoms and treatment
Number of subjects: 3522

Group type: EXPERIMENTAL
Intervention: Higher knowledge scores
Number of subjects: 3522

Group type: EXPERIMENTAL
Intervention: Self-perceived risk for future AMI
Number of subjects: 3522

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 3522
Study: 17136007

Group type: EXPERIMENTAL
Intervention: Irradiated blood products (40 Gy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-irradiated blood products
Number of subjects: 20
Study: 14510909

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10751266

Group type: COMPARATOR
Intervention: CSF tau
Number of subjects: 35

Group type: COMPARATOR
Intervention: AD7C‐NTP
Number of subjects: 35

Group type: COMPARATOR
Intervention: Combined evaluation of tau and AD7C‐NTP
Number of subjects: 35

Group type: COMPARATOR
Intervention: tau
Number of subjects: 35
Study: 9223837

Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice daily (90%) or 2.5 mg once daily (10%)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 94
Study: 8310765

Group type: EXPERIMENTAL
Intervention: Schedule A (0-1-2-12 months)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Schedule B (0-1-6 months)
Number of subjects: 200
Study: 3526773

Group type: EXPERIMENTAL
Intervention: Combination of ampicillin, mecillinam and metronidazole (group I)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cefoxitin (group II)
Number of subjects: 168
Study: 30526573

Group type: EXPERIMENTAL
Intervention: Face-to-face EBM training
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Community management of hypertension (Face-to-face EBM training)
Number of subjects: 151
Study: 27909310

Group type: EXPERIMENTAL
Intervention: 100% serum eye drops for PED
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional treatments (historical control)
Number of subjects: 109
Study: 24610862

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg once-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once-daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine (control)
Number of subjects: 0
Study: 23782969

Group type: EXPERIMENTAL
Intervention: Central venous catheters
Number of subjects: 263

Group type: COMPARATOR
Intervention: Peripheral venous catheters
Number of subjects: 263

Group type: COMPARATOR
Intervention: Peripheral venous catheters only
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Peripheral and central venous catheters
Number of subjects: 263
Study: 19477145

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12
Study: 18822498

Group type: EXPERIMENTAL
Intervention: Vaccine against Haemophilus influenzae type b administered simultaneously with diphtheria-tetanus-whole cell pertussis and inactivated polio vaccines (Imovax Polio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine against Haemophilus influenzae type b
Number of subjects: 0
Study: 16912120

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 25, 50, 125, 300, or 600 mg weekly for 5 months
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 125, 300, and 600 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 121
Study: 12522515

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 or 400 mg/d
Number of subjects: 3258

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 to 400 mg/d
Number of subjects: 3258

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/d
Number of subjects: 3258

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d
Number of subjects: 3258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3258
Study: 11144049

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 8578831

Group type: EXPERIMENTAL
Intervention: 1.4 x 10(3) c.f.u. S. flexneri 2a
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1.4 x 10(2) c.f.u. S. flexneri 2a
Number of subjects: 23
Study: 2527130

Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Human lente insulin
Number of subjects: 66
Study: 336079

Group type: EXPERIMENTAL
Intervention: Peripheral retinal ablation using the argon laser
Number of subjects: 94

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 94
Study: 31414884

Group type: EXPERIMENTAL
Intervention: Harmonized templates after quality improvement initiative
Number of subjects: 19687

Group type: EXPERIMENTAL
Intervention: Radiologist adherence to harmonized templates
Number of subjects: 19687
Study: 29059273

Group type: EXPERIMENTAL
Intervention: Tasquinimod (0.25-1.0 mg/day orally)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 144
Study: 26525022

Group type: EXPERIMENTAL
Intervention: Butylphthalide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Xue Shuan Tong
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butylphthalide and Xue Shuan Tong
Number of subjects: 120
Study: 23945520

Group type: EXPERIMENTAL
Intervention: 0.5 cc mDHACM
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.25 cc mDHACM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (1.25 cc saline)
Number of subjects: 45
Study: 20859637

Group type: EXPERIMENTAL
Intervention: 100% IAT
Number of subjects: 25

Group type: COMPARATOR
Intervention: 80% IAT
Number of subjects: 25
Study: 17892885

Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of EX/RP and CMI (EX/RP&CMI)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 122
Study: 16996868

Group type: EXPERIMENTAL
Intervention: Verapamil SR
Number of subjects: 16176

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 16176

Group type: EXPERIMENTAL
Intervention: Verapamil SR with trandolapril
Number of subjects: 16176

Group type: EXPERIMENTAL
Intervention: Atenolol with hydrochlorothiazide
Number of subjects: 16176
Study: 14622688

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg x kg(‐1) body weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11049949

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.12% unoprostone
Number of subjects: 40
Study: 9083230

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norepinephrine-Dobutamine
Number of subjects: 30
Study: 8460916

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg orally every 12 h)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 3539462

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 9
Study: 31403815

Group type: EXPERIMENTAL
Intervention: Groups 4 Health (G4H)
Number of subjects: 120
Study: 29283674

Group type: EXPERIMENTAL
Intervention: Blended educational experience with video narratives and direct interactions with people affected by IDD
Number of subjects: 27

Group type: COMPARATOR
Intervention: Introductory video lecture about IDD healthcare
Number of subjects: 27
Study: 27349621

Group type: EXPERIMENTAL
Intervention: INTERACT quality improvement program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transfers within 48 hours or 30 days
Number of subjects: 64
Study: 25580060

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg/day for 6 months)
Number of subjects: 52
Study: 22467928

Group type: EXPERIMENTAL
Intervention: MACTAR
Number of subjects: 192
Study: 19890266

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (10 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 18831930

Group type: EXPERIMENTAL
Intervention: Inhaled thiamphenicol associated with acetylcysteine (250 mg: 1/2 vial in the morning and 1/2 vial in the evening) for 5 days (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline solution twice daily for 5 days (Group B)
Number of subjects: 90
Study: 15838660

Group type: EXPERIMENTAL
Intervention: Schedule A: Docetaxel 60 mg/m² over 1 hour followed by Topotecan 0.85 mg/m² continuous infusion over 72 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Schedule B: Topotecan 0.85 mg/m² continuous infusion over 72 hours followed by Docetaxel 60 mg/m² over 1 hour
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Schedule B
Number of subjects: 30
Study: 11866182

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: De‐nicotinized cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes or instructions indicating nicotine content
Number of subjects: 0
Study: 10517908

Group type: EXPERIMENTAL
Intervention: 60 mg oral diltiazem
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Once daily diltiazem
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twice daily diltiazem
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% diltiazem gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% bethanechol gel
Number of subjects: 30
Study: 7563935

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-G-CSF
Number of subjects: 64
Study: 1891681

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aerosol (400 micrograms once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Budesonide dry powder (400 micrograms once daily)
Number of subjects: 60
Study: 6337323

Group type: EXPERIMENTAL
Intervention: Protective environment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Moderately severe to severe acute GVHD
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Refractoriness to random-donor platelet infusions at transplantation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 130

Group type: COMPARATOR
Intervention: Acute or chronic graft-versus-host disease (GVHD)
Number of subjects: 130
Study: 30745097

Group type: EXPERIMENTAL
Intervention: NIT+IPC (NO3‐‐rich gel ingested 90min prior to testing)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLA+IPC (low NO3‐ placebo ingested 90min prior to testing)
Number of subjects: 10

Group type: COMPARATOR
Intervention: BASE (no dietary intervention or IPC)
Number of subjects: 10
Study: 30081338

Group type: EXPERIMENTAL
Intervention: Brief therapy (BT)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both BT and XR-NTX
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Older age, white race, talking with a professional about alcohol use, and having more negative consequences
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Not being homeless and previously talking with a professional
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Older age, white race, and experiencing more negative consequences
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Receipt of BT preceding XR-NTX
Number of subjects: 290
Study: 27068751

Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 312

Group type: COMPARATOR
Intervention: Combined
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 312
Study: 25226881

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study: 23042313

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 185

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) therapy
Number of subjects: 185
Study: 19409546

Group type: EXPERIMENTAL
Intervention: Group C (three coagulation points per ovary)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D (four to five coagulation points per ovary)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group A (one coagulation point per ovary)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B (two coagulation points per ovary)
Number of subjects: 80
Study: 18565887

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with temozolomide (n = 42)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with temozolomide
Number of subjects: 80
Study: 15997317

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccines (WHO‐17D and Brazilian 17DD substrains)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study: 11893094

Group type: EXPERIMENTAL
Intervention: DB+AD
Number of subjects: 169

Group type: COMPARATOR
Intervention: DB-only
Number of subjects: 169
Study: 10051263

Group type: EXPERIMENTAL
Intervention: Aspirin (1,000 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paracetamol (1,000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LPS (4 ng/kg)
Number of subjects: 30
Study: 8808181

Group type: EXPERIMENTAL
Intervention: 6 micrograms of formoterol (F6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 12 micrograms of formoterol (F12)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 24 micrograms of formoterol (F24)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 1851065

Group type: EXPERIMENTAL
Intervention: Borg scale estimates of breathlessness
Number of subjects: 0
Study: 7006441

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine 0.5% (mean dose 112.8 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pethidine (mean dose 200 mg) and inhalational analgesia
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Epidural analgesia and Pethidine
Number of subjects: 93
Study: 31151474

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 28835192

Group type: EXPERIMENTAL
Intervention: Active flexion added to modified Kleinert regime
Number of subjects: 53

Group type: COMPARATOR
Intervention: Modified Kleinert regime
Number of subjects: 53
Study: 25147125

Group type: EXPERIMENTAL
Intervention: Water intake during meals
Number of subjects: 28

Group type: COMPARATOR
Intervention: No water intake during meals
Number of subjects: 28
Study: 23380214

Group type: EXPERIMENTAL
Intervention: Collateral Meridian (CM) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study: 22878599

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 354

Group type: COMPARATOR
Intervention: No iliac crest autograft (Control)
Number of subjects: 354
Study: 20353746

Group type: EXPERIMENTAL
Intervention: Modified-release formulation of diltiazem hydrochloride (240 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation with highest amount of polysaccharide in coating
Number of subjects: 0
Study: 17937084

Group type: EXPERIMENTAL
Intervention: Acupuncture (performed biweekly from day 5 of the follicular phase through the luteal phase, not on the day of embryo transfer)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (matched according to age, previous failed IVF cycles, and type of embryo transfer)
Number of subjects: 32